

3rd Annual Next Gen

Immuno-Oncology Congress

14th - 15th March 2019 • London, UK



Event overview

Over the past several years, many immuno-oncology modalities have emerged. These modalities, which include checkpoint inhibition, adoptive T-cell therapy (ACT), and cancer vaccines, are often designed to evade immune responses. This is a rapidly growing therapeutic field that embraces the concept of modulating the immune system to recognize tumor cells and target them for destruction. Our **Next-gen immuno-oncology congress** from past 2 years had gathered the professionals across the globe to deliver such latest developments.

Having completed two extremely successful editions, we are coming up with “3rd Annual Next-Gen Immuno-Oncology Congress” gathering the academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Immune Checkpoint Inhibitors and Adoptive Cellular Therapy.

Key Highlights:

- ▶ Updates in development of monoclonal ADC’s and Bispecific Ab’s
- ▶ Immune Checkpoint Inhibitors and Combinations
- ▶ Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immunecheckpoint modulators)
- ▶ Biomarkers and Cancer Vaccines
- ▶ CAR-T cell therapy, Adoptive Cell Therapy
- ▶ Tumor microenvironment
- ▶ Oncolytic Viruses

Who Should Attend?

Monoclonal and Bispecific Antibodies	Cell Therapy	Immune Checkpoint Inhibitors
<ul style="list-style-type: none">• ADCs development Preclinical and Translational Oncology• Oncology• Bi-specifics- Preclinical and Translational• Clinical development• R&D- Discovery and process• PKPD/ADME/Tox• Antibody Engineering• Antibody therapeutics• Physio-Chemistry /Synthetic Chemistry and/ Bio conjugation• Bioanalysis	<ul style="list-style-type: none">• Oncology• Clinical development• R&D- discovery and process• Discovery• Target Validation• Bioanalysis• Therapeutic areas• PKPD/ADME/Tox• Biologics -antibody• Cell-Based Immunotherapies• Innate and adaptive immune cells• Antibody engineering Tumour antigens and neoantigens	<ul style="list-style-type: none">• Cancer immunotherapy• Immune checkpoint targets• Checkpoint inhibition• Cellular therapy• Clinical research• Combination therapy• Cancer Vaccines• Preclinical and Translational Oncology R&D• Immune biomarkers• Immunology• Cancer biology• Immuno-oncology• Tumour-associated mechanisms of immune suppression

Why Attend?

- Find out new case studies of antibody projects in development
- Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you
- Explore the latest platforms and technologies on the market for development
- Discuss the best tool for your research in immune-oncology
- Share your work and achievements with your industry peers in the Poster Session

3rd Annual Next Gen

Immuno-Oncology Congress

14th - 15th March 2019 • London, UK

Advisory Panel

- **Eugene Zhukovsky**, Chief Scientific Officer, **Biomunex Pharmaceuticals, France**
- **Jeanette Leusen**, Group Leader, Tumor Immunology, **UMC Utrecht, Netherlands**
- **Sophia Karagiannis**, Head of Cancer Antibody Discovery and Immunotherapy, **King's College London, UK**

Expert Speaker Panel

- **Eugene Zhukovsky**, Chief Scientific Officer, **Biomunex Pharmaceuticals, France**
- **Jeanette Leusen**, Group Leader, Tumor Immunology, **UMC Utrecht, Netherlands**
- **Sophia Karagiannis**, Head of Cancer Antibody Discovery and Immunotherapy, **King's College London, UK**
- **Thomas Valerius**, Professor-Department of stem cell and immunotherapy, **Kiel Life Science, Germany**
- **Lindy Durrant**, Professor, Cancer Immunotherapy, **The University of Nottingham, UK**
- **Steven Schellings**, Associate Director, Cellular Therapy, **Novartis, USA**
- **Matthias Friedrich**, Scientific Director, **Amgen, Germany**
- **Matthias Peipp**, Professor, Group Leader, **University of Kiel, Germany**
- **Livija Deban**, VP Immunology and Oncology, **Prokarium, UK**
- **Stefan Glueck**, Vice President, Global Medical Affairs, **Celgene, USA**
- **Hardev Panda**, Professor of Medical Oncology, **University of Surrey, UK**
- **Kandeepan Ganeshaligam**, Executive Director, Therapeutic Area, **Merck, USA**
- **Laura Kenny**, Clinical Senior Lecturer, Medical Oncology, **Imperial College of London, UK**
- **Robert Hawkins**, Professor Cancer Research Campaign, **University of Manchester, UK**
- **Michelle Morrow**, Vice President, Preclinical and Translational Pharmacology, **F-Star Biotechnology Ltd, UK**
- **Thierry Wurch**, Director, External Research & Innovation, **Servier, France**

Sponsor/Exhibitor

MYRIAD  RBM®

3rd Annual Next Gen

Immuno-Oncology Congress

14th - 15th March 2019 • London, UK

Day 1 - Thursday 14th March, 2019

08:15 Registration
08:55 Welcome note from MarketsandMarkets

STREAM A		STREAM B			
Monoclonal and Bispecific Antibodies		Immune Checkpoint Inhibitors & Combination Strategies			
9:00	Opening remarks from the Chairman	9:00	Opening remarks from the Chairman		
9:05	Keynote: Engineering and Screening Effective and Manufacturable IgG-like Therapeutics	9:05	Keynote: Innate Immune Agonists for combination with CPIs TLR7, TLR9, Sting, RIG-I, Mda5		
9:35	Increasing specificity of targeting employing bispecific antibodies	9:35	CPI combination with chemotherapy and radiation		
10:05	<i>Solution Provider Presentation-Please contact sanjib.biswas@marketsandmarkets.com</i>	10:05	<i>Solution Provider Presentation-Please contact sanjib.biswas@marketsandmarkets.com</i>		
10:35 Morning Refreshments and Poster Presentations One-to-One Networking Meetings					
Targeted Antibodies and Combinations		Pre-clinical & Translational Immuno-Oncology Developments			
11:25	Novel conjugation technologies-Payload and Linkers	11:25	Pre-clinical models for Immune Checkpoint Modulators		
11:55	Improving recruitment of myeloid effector cells for antibody therapy: impact of antibody isotype and CD47/SIRPa checkpoint blockade <ul style="list-style-type: none"> • Myeloid cells contribute to antibody efficacy • Human IgG2 and IgA isotypes selectively improve myeloid cell recruitment • Tumor cell killing by myeloid cells is enhanced by CD47/SIRPa interference Thomas Valerius , Professor-Department of stem cell and immunotherapy, Kiel Life Science, Germany	11:55	Creating novel hypotheses and evaluation in translational research		
12:25	Therapeutic targeting of the tumor microenvironment	12:25	Role of predictive biomarkers in patient enrichment strategies		
12:55 Lunch and Poster Presentations One-to-One Networking Meetings					
STREAM A		STREAM B		STREAM C	
Monoclonal and Bispecific Antibodies		Immune Checkpoint Inhibitors		Cellular Therapy	
New Antibody Formats		New Immune Checkpoints for Immunotherapy		Developments in CAR-T Cell Therapy and Vaccines	
13:55	Monoclonal antibody approaches for triple-negative breast cancer <ul style="list-style-type: none"> • Highly-aggressive triple negative forms of breast cancer (TNBCs) lack validated targets and effective systemic therapies. • We demonstrate that the tumor-associated antigen Folate Receptor alpha (FRα) is overexpressed in subsets of TNBCs and may present a targetable molecule for monoclonal antibody therapy against TNBC. • A monoclonal antibody recognizing FRα triggered immune-dependent FRα-expressing breast cancer cell death by healthy volunteer and breast cancer patient effector cells, and significantly restricted orthotopic TNBC line and patient-derived tumor xenograft growth. Sophia Karagiannis , Head of Cancer Antibody Discovery and Immunotherapy, King's College London, UK	13:55	Combination Strategies to Overcome Resistance to Anti-PD-1/PD-L1 Therapies	13:55	Development of a New Generation of DNA Vaccines

3rd Annual Next Gen

Immuno-Oncology Congress

14th - 15th March 2019 • London, UK

Day 1 - Thursday 14th March, 2019

STREAM A		STREAM B		STREAM C	
14:35	<i>Solution Provider Presentation-Please contact sanjib.biswas@marketsandmarkets.com</i>	14:35	<i>Solution Provider Presentation-Please contact sanjib.biswas@marketsandmarkets.com</i>	14:35	<i>Solution Provider Presentation-Please contact sanjib.biswas@marketsandmarkets.com</i>
15:05	Break Out Session	15:05	Panel Discussion: Future of Biologics in Immune Checkpoint therapy	15:05	Break Out Session
15:35	<i>Solution Provider Presentation-Please contact sanjib.biswas@marketsandmarkets.com</i>	15:35	<i>Solution Provider Presentation-Please contact sanjib.biswas@marketsandmarkets.com</i>	15:35	<i>Solution Provider Presentation-Please contact sanjib.biswas@marketsandmarkets.com</i>
16:05	Evening Refreshments and Poster Presentations One-to-One Networking Meetings				
16:55	Novel Bispecific PD-1 antibody therapeutic approach in solid tumours	16:55	Agonist checkpoint combination studies	16:55	Bispecific T-Cell engagers for cancer immunotherapy
17:25	Bicycle Drug Conjugate for treatment of solid tumours	17:25	Biomarkers for prognosis and prediction to immunotherapies	17:25	Synthetic Biology in Cellular Immunotherapy

17:55 Closing remarks from the Chairman

18:00 End of Conference

3rd Annual Next Gen

Immuno-Oncology Congress

14th - 15th March 2019 • London, UK

Day 2 - Friday 15th March, 2019

08:15 Registration

08:55 Welcome note from MarketsandMarkets

STREAM A		STREAM B		STREAM C	
Monoclonal and Bispecific Antibodies		Immune Checkpoint Inhibitors		Cellular Therapy	
09:00	Opening remarks from the Chairman	09:00	Opening remarks from the Chairman	09:00	Opening remarks from the Chairman
New Antibodies Development and Tumor Microenvironment		Personalized Immunotherapy and Viral Therapies		Technologies for Personalized T Cell Receptor Engineered Cancer Immunotherapies	
9:05	Keynote: Emerging classes of armed antibody therapeutics	9:05	Keynote: Improving efficacy of CPI's by selected combination therapy	9:05	Keynote: Precision Immunology for targeted therapy
	9:35 Challenges in the clinical development of ADC's		9:35 Novel mRNA-based Immunotherapy Vaccines		9:35 Adoptive T-Cell Immunotherapy
10:05	<i>Solution Provider Presentation-Please contact sanjib.biswas@marketsandmarkets.com</i>	10:05	<i>Solution Provider Presentation-Please contact sanjib.biswas@marketsandmarkets.com</i>	10:05	<i>Solution Provider Presentation-Please contact sanjib.biswas@marketsandmarkets.com</i>
10:35 Morning Refreshments and Poster Presentations One-to-One Networking Meetings					
11:25	Recombinant antibodies for immunotherapy	11:25	Tumor neo-epitopes and their use in personalizing cancer immunotherapies	11:25	The Role of Dynamic Tumor and Immune Sampling in Immunotherapy
11:55	Understanding drug interaction potential for antibody drug conjugates in clinical development	11:55	Systematic Approaches to Identifying and Overcoming Resistance to Immune Checkpoint Inhibitors	11:55	Translational approach in developing right IO's
12:25	Role of Immune Activation Profiling in clinical trials	12:25	Oncolytic viruses in the era of Checkpoint Blockade	12:25	Treatment of MSI tumors and their superior response to immunotherapy
12:55 Lunch and Poster Presentations One-to-One Networking Meetings					
STREAM A			STREAM B		
Monoclonal & Bispecific Antibodies			Immune Checkpoint Inhibitors and Combination Strategies		
13:55	Study of cytotoxic payloads-in vivo assays and efficacy testing		13:55	Role of Nanotechnology with a combinatorial approach for solid tumors	
14:25	<i>Solution Provider Presentation-Please contact sanjib.biswas@marketsandmarkets.com</i>		14:25	<i>Solution Provider Presentation-Please contact sanjib.biswas@marketsandmarkets.com</i>	
14:55	Predicting the toxicity of Immuno-Oncology studies		14:55	Future opportunities in clinical development of ICI combinations	

15:25 Closing remarks from the Chairman

15:30 End of Conference